Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice

The concept of fitness for novel agents in chronic lymphocytic leukemia (CLL) remains debated. Comorbidities and treatment-related logistics are increasingly recognized as key factors in treatment feasibility. Venetoclax-obinutuzumab (VO) has demonstrated efficacy in both fit and unfit patients in...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Anna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, Lorena Appio, Jacopo Olivieri, Alessandro Sanna, Claudia Baraté, Fabrizio Pane, Luana Schiattone, Beatrice Casadei, Isacco Ferrarini, Amalia Figuera, Paolo Sportoletti, Giacomo Loseto, Caterina Stelitano, Andrea Visentin, Melania Celli, Francesca Romana Mauro, Massimiliano Palombi, Marta Coscia, Vanessa Innao, Riccardo Moia, Marina Motta, Filomena Russo, Monica Tani, Annalisa Arcari, Elia Boccellato, Chiara Borella, Enrico Capochiani, Angela Ferrari, Massimo Gentile, Roberta Giachetti, Annamaria Giordano, Martina Bullo, Enrico Lista, Luigi Malandruccolo, Maurizio Musso, Marzia Varettoni, Federico Vozella, Francesca Cibien, Michele Merli, Laura Nocilli, Maria Cristina Pasquini, Azzurra Anna Romeo, Valentina Rossi, Gloria Turri, Anna Vanazzi, Marina Cavaliere, Alessandro Gozzetti, Lara Crucitti, Moira Lucesole, Marina Deodato, Annamaria Tomasso, Arianna Zappaterra, Roberta Murru, Caterina Patti, Luca Laurenti, Alessandra Tedeschi
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Ferrata Storti Foundation 2025-06-01
Цуврал:	Haematologica
Онлайн хандалт:	https://haematologica.org/article/view/12141
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!